APA (7th ed.) Citation

CR, H., AS, B., I, H., SW, S., J, J., J, O., . . . R, Z. (2025). Eliminating the high-risk CTV1 margin in DAHANCA oropharyngeal radiotherapy: Dosimetric impact on dysphagia and organ-at-risk doses. Acta oncologica (Stockholm, Sweden), 64, 1205. https://doi.org/10.2340/1651-226X.2025.44049

Chicago Style (17th ed.) Citation

CR, Hansen, Bertelsen AS, Hazell I, Stougaard SW, Johansen J, Overgaard J, Eriksen JG, and Zukauskaite R. "Eliminating the High-risk CTV1 Margin in DAHANCA Oropharyngeal Radiotherapy: Dosimetric Impact on Dysphagia and Organ-at-risk Doses." Acta Oncologica (Stockholm, Sweden) 64 (2025): 1205. https://doi.org/10.2340/1651-226X.2025.44049.

MLA (9th ed.) Citation

CR, Hansen, et al. "Eliminating the High-risk CTV1 Margin in DAHANCA Oropharyngeal Radiotherapy: Dosimetric Impact on Dysphagia and Organ-at-risk Doses." Acta Oncologica (Stockholm, Sweden), vol. 64, 2025, p. 1205, https://doi.org/10.2340/1651-226X.2025.44049.